{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T16:30:19Z","timestamp":1794328219468,"version":"4.9.0"},"reference-count":28,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,1,14]]},"abstract":"<jats:title>Key Points<\/jats:title>\n               <jats:p>Larotrectinib has clinical activity in adult Ph-like acute lymphoblastic leukemia with ETV6-NTRK3 rearrangements. ETV6-NTRK3 rearrangements can be cryptic and subclonal in Ph-like ALL at diagnosis and selected for with aggressive therapy.<\/jats:p>","DOI":"10.1182\/bloodadvances.2019000769","type":"journal-article","created":{"date-parts":[[2020,1,6]],"date-time":"2020-01-06T11:33:36Z","timestamp":1578310416000},"page":"106-111","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":31,"title":["Clinical response to larotrectinib in adult Philadelphia chromosome\u2013like ALL with cryptic ETV6-NTRK3 rearrangement"],"prefix":"10.1182","volume":"4","author":[{"given":"Valentina","family":"Nardi","sequence":"first","affiliation":[{"name":"Harvard Medical School, Boston, MA;"},{"name":"Department of Pathology, Massachusetts General Hospital, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nora","family":"Ku","sequence":"additional","affiliation":[{"name":"Loxo Oncology, South San Francisco, CA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew J.","family":"Frigault","sequence":"additional","affiliation":[{"name":"Harvard Medical School, Boston, MA;"},{"name":"Cancer Center, Massachusetts General Hospital, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian M.","family":"Dubuc","sequence":"additional","affiliation":[{"name":"Harvard Medical School, Boston, MA;"},{"name":"Department of Pathology, Brigham and Women\u2019s Hospital, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harrison Kwei","family":"Tsai","sequence":"additional","affiliation":[{"name":"Harvard Medical School, Boston, MA;"},{"name":"Department of Pathology, Brigham and Women\u2019s Hospital, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip C.","family":"Amrein","sequence":"additional","affiliation":[{"name":"Harvard Medical School, Boston, MA;"},{"name":"Cancer Center, Massachusetts General Hospital, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0199-9333","authenticated-orcid":false,"given":"Gabriela S.","family":"Hobbs","sequence":"additional","affiliation":[{"name":"Harvard Medical School, Boston, MA;"},{"name":"Cancer Center, Massachusetts General Hospital, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew M.","family":"Brunner","sequence":"additional","affiliation":[{"name":"Harvard Medical School, Boston, MA;"},{"name":"Cancer Center, Massachusetts General Hospital, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rupa","family":"Narayan","sequence":"additional","affiliation":[{"name":"Harvard Medical School, Boston, MA;"},{"name":"Cancer Center, Massachusetts General Hospital, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meghan E.","family":"Burke","sequence":"additional","affiliation":[{"name":"Harvard Medical School, Boston, MA;"},{"name":"Cancer Center, Massachusetts General Hospital, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Foster","sequence":"additional","affiliation":[{"name":"Harvard Medical School, Boston, MA;"},{"name":"Cancer Center, Massachusetts General Hospital, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Dal Cin","sequence":"additional","affiliation":[{"name":"Harvard Medical School, Boston, MA;"},{"name":"Department of Pathology, Brigham and Women\u2019s Hospital, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7578-0393","authenticated-orcid":false,"given":"Marcela V.","family":"Maus","sequence":"additional","affiliation":[{"name":"Harvard Medical School, Boston, MA;"},{"name":"Cancer Center, Massachusetts General Hospital, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir T.","family":"Fathi","sequence":"additional","affiliation":[{"name":"Harvard Medical School, Boston, MA;"},{"name":"Cancer Center, Massachusetts General Hospital, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanno","family":"Hock","sequence":"additional","affiliation":[{"name":"Harvard Medical School, Boston, MA;"},{"name":"Cancer Center, Massachusetts General Hospital, Boston, MA;"},{"name":"Center for Regenerative Medicine, Massachusetts General Hospital, Boston, MA; and"},{"name":"Harvard Stem Cell Institute, Cambridge, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2020,1,6]]},"reference":[{"issue":"2","key":"2020010611333035100_B1","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1007\/s11899-019-00503-1","article-title":"Recent advances in adult acute lymphoblastic leukemia","volume":"14","author":"Richard-Carpentier","year":"2019","journal-title":"Curr Hematol Malig Rep"},{"issue":"2","key":"2020010611333035100_B2","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S1470-2045(08)70339-5","article-title":"A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study","volume":"10","author":"Den Boer","year":"2009","journal-title":"Lancet Oncol"},{"issue":"5","key":"2020010611333035100_B3","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1056\/NEJMoa0808253","article-title":"Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia","volume":"360","author":"Mullighan","year":"2009","journal-title":"N Engl J Med"},{"issue":"11","key":"2020010611333035100_B4","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1056\/NEJMoa1403088","article-title":"Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia","volume":"371","author":"Roberts","year":"2014","journal-title":"N Engl J Med"},{"issue":"4","key":"2020010611333035100_B5","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.beha.2018.09.003","article-title":"Why and how to treat Ph-like ALL?","volume":"31","author":"Roberts","year":"2018","journal-title":"Best Pract Res Clin Haematol"},{"issue":"8","key":"2020010611333035100_B6","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1182\/blood-2018-05-849554","article-title":"ETV6-NTRK3 induces aggressive acute lymphoblastic leukemia highly sensitive to selective TRK inhibition","volume":"132","author":"Roberts","year":"2018","journal-title":"Blood"},{"key":"2020010611333035100_B7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.humpath.2018.11.022","article-title":"Clinicopathological and molecular features of SF3B1-mutated myeloproliferative neoplasms","volume":"86","author":"Boiocchi","year":"2019","journal-title":"Hum Pathol"},{"issue":"12","key":"2020010611333035100_B8","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1038\/nm.3729","article-title":"Anchored multiplex PCR for targeted next-generation sequencing","volume":"20","author":"Zheng","year":"2014","journal-title":"Nat Med"},{"issue":"1","key":"2020010611333035100_B9","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.jmoldx.2018.08.003","article-title":"A nanopore sequencing-based assay for rapid detection of gene fusions","volume":"21","author":"Jeck","year":"2019","journal-title":"J Mol Diagn"},{"key":"2020010611333035100_B10","first-page":"3997","article-title":"Aligning sequence reads, clone sequences and assembly contigs with BWA-MEM","volume-title":"arXiv","author":"Li","year":"2013"},{"issue":"7","key":"2020010611333035100_B11","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1097\/PAS.0000000000001062","article-title":"Pan-Trk immunohistochemistry identifies NTRK rearrangements in pediatric mesenchymal tumors","volume":"42","author":"Rudzinski","year":"2018","journal-title":"Am J Surg Pathol"},{"issue":"2","key":"2020010611333035100_B12","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1053\/j.seminhematol.2017.04.005","article-title":"ETV6 in hematopoiesis and leukemia predisposition","volume":"54","author":"Hock","year":"2017","journal-title":"Semin Hematol"},{"issue":"7337","key":"2020010611333035100_B13","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/nature09727","article-title":"CREBBP mutations in relapsed acute lymphoblastic leukaemia","volume":"471","author":"Mullighan","year":"2011","journal-title":"Nature"},{"issue":"4","key":"2020010611333035100_B14","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1182\/blood.V93.4.1355","article-title":"Fusion of ETV6 to neurotrophin-3 receptor TRKC in acute myeloid leukemia with t(12;15)(p13;q25)","volume":"93","author":"Eguchi","year":"1999","journal-title":"Blood"},{"issue":"22","key":"2020010611333035100_B15","first-page":"5046","article-title":"ETV6-NTRK3 gene fusions and trisomy 11 establish a histogenetic link between mesoblastic nephroma and congenital fibrosarcoma","volume":"58","author":"Knezevich","year":"1998","journal-title":"Cancer Res"},{"issue":"suppl 1","key":"2020010611333035100_B16","article-title":"Phase I study of ixazomib in addition to chemotherapy for the treatment of acute lymphoblastic leukemia in older adults [abstract]","volume":"132","author":"Amrein","year":"2018","journal-title":"Blood"},{"issue":"2","key":"2020010611333035100_B17","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","article-title":"Current concepts in the diagnosis and management of cytokine release syndrome [published correction appears in Blood. 2015;126(8):1048]","volume":"124","author":"Lee","year":"2014","journal-title":"Blood"},{"issue":"9","key":"2020010611333035100_B18","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1056\/NEJMoa1609783","article-title":"Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia","volume":"376","author":"Kantarjian","year":"2017","journal-title":"N Engl J Med"},{"issue":"8","key":"2020010611333035100_B19","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1056\/NEJMoa1509277","article-title":"Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia","volume":"375","author":"Kantarjian","year":"2016","journal-title":"N Engl J Med"},{"issue":"1","key":"2020010611333035100_B20","first-page":"11","article-title":"High-dose cytosine arabinoside and mitoxantrone (HAM) for the treatment of refractory acute lymphoblastic leukemia","volume":"10","author":"Hiddemann","year":"1987","journal-title":"Onkologie"},{"issue":"40","key":"2020010611333035100_B21","doi-asserted-by":"crossref","first-page":"11306","DOI":"10.1073\/pnas.1608420113","article-title":"Mutational landscape, clonal evolution patterns, and role of RAS mutations in relapsed acute lymphoblastic leukemia","volume":"113","author":"Oshima","year":"2016","journal-title":"Proc Natl Acad Sci USA"},{"issue":"8","key":"2020010611333035100_B22","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1056\/NEJMoa1714448","article-title":"Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children","volume":"378","author":"Drilon","year":"2018","journal-title":"N Engl J Med"},{"issue":"3","key":"2020010611333035100_B23","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1182\/blood.V56.3.351.351","article-title":"Serum lactic dehydrogenase (LDH) levels in acute leukemia: marked elevations in lymphoblastic leukemia","volume":"56","author":"Kornberg","year":"1980","journal-title":"Blood"},{"issue":"12","key":"2020010611333035100_B24","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/s41571-018-0113-0","article-title":"NTRK fusion-positive cancers and TRK inhibitor therapy","volume":"15","author":"Cocco","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"issue":"6","key":"2020010611333035100_B25","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.ccr.2007.11.012","article-title":"ETV6-NTRK3 fusion oncogene initiates breast cancer from committed mammary progenitors via activation of AP1 complex","volume":"12","author":"Li","year":"2007","journal-title":"Cancer Cell"},{"issue":"9","key":"2020010611333035100_B26","doi-asserted-by":"crossref","first-page":"3819","DOI":"10.1172\/JCI120787","article-title":"Oncogenic TRK fusions are amenable to inhibition in hematologic malignancies","volume":"128","author":"Taylor","year":"2018","journal-title":"J Clin Invest"},{"issue":"11","key":"2020010611333035100_B27","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1038\/nm.3352","article-title":"Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer","volume":"19","author":"Vaishnavi","year":"2013","journal-title":"Nat Med"},{"issue":"1","key":"2020010611333035100_B28","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.cell.2019.02.049","article-title":"A tumor-agnostic NTRK (TRK) inhibitor","volume":"177","author":"Huang","year":"2019","journal-title":"Cell"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/4\/1\/106\/1551050\/advancesadv2019000769.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/4\/1\/106\/1551050\/advancesadv2019000769.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,1,6]],"date-time":"2020-01-06T11:33:55Z","timestamp":1578310435000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/4\/1\/106\/430054\/Clinical-response-to-larotrectinib-in-adult"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,6]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1,14]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2019000769","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,6]]}}}